← FDA DRUG APPROVALS

FDA ANDA · ANDA065036

IDARUBICIN HYDROCHLORIDE

Sponsor: MEITHEAL

APPLICATION
ANDA065036
TYPE
ANDA
ORIGINAL APPROVAL
2002-05-01
LATEST ACTION
2023-03-27
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

IDARUBICIN HYDROCHLORIDEPrescription
IDARUBICIN HYDROCHLORIDE 10MG/10ML (1MG/ML) · SOLUTION · INTRAVENOUS
IDARUBICIN HYDROCHLORIDEPrescription
IDARUBICIN HYDROCHLORIDE 20MG/20ML (1MG/ML) · SOLUTION · INTRAVENOUS
IDARUBICIN HYDROCHLORIDEPrescription
IDARUBICIN HYDROCHLORIDE 5MG/5ML (1MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2023-03-27Labeling · Supplement 34 · standardAP
2022-01-27Labeling · Supplement 33 · standardAP
2020-04-27Labeling · Supplement 27 · standardAP
2020-04-27Labeling · Supplement 30 · standardAP
2011-11-22Labeling · Supplement 19AP
2002-05-01OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →